CA2607176A1 - Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents - Google Patents

Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents Download PDF

Info

Publication number
CA2607176A1
CA2607176A1 CA002607176A CA2607176A CA2607176A1 CA 2607176 A1 CA2607176 A1 CA 2607176A1 CA 002607176 A CA002607176 A CA 002607176A CA 2607176 A CA2607176 A CA 2607176A CA 2607176 A1 CA2607176 A1 CA 2607176A1
Authority
CA
Canada
Prior art keywords
als
candida
mice
albicans
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002607176A
Other languages
English (en)
French (fr)
Inventor
John E. Edwards, Jr.
Scott G. Filler
Donald C. Sheppard
Ashraf Ibrahim
Yue Fu
Brad J. Spellberg
Michael Yeaman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2607176A1 publication Critical patent/CA2607176A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0002Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002607176A 2005-05-05 2006-05-04 Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents Abandoned CA2607176A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/123,873 US20060083750A1 (en) 1999-11-19 2005-05-05 Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US11/123,873 2005-05-05
PCT/US2006/017482 WO2006121895A2 (en) 2005-05-05 2006-05-04 Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents

Publications (1)

Publication Number Publication Date
CA2607176A1 true CA2607176A1 (en) 2006-11-16

Family

ID=37397150

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002607176A Abandoned CA2607176A1 (en) 2005-05-05 2006-05-04 Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents

Country Status (6)

Country Link
US (1) US20060083750A1 (enExample)
EP (1) EP1883421A4 (enExample)
JP (1) JP2008540453A (enExample)
AU (1) AU2006244401B2 (enExample)
CA (1) CA2607176A1 (enExample)
WO (1) WO2006121895A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
RU2015122387A (ru) * 2009-07-03 2015-10-27 Лос-Анжелес Биомедикал Ресёрч Институт Эт Харбор-Укла Медикал Центер Hyr1 в качестве мишени для активной и пассивной иммунизации против candida
CA2871081A1 (en) * 2011-04-21 2012-10-26 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Peptide and conjugate vaccines for fungal infections
CN103998056B (zh) * 2011-07-22 2017-09-12 诺瓦蒂格姆疗法有限公司 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
EA030005B1 (ru) 2013-03-15 2018-06-29 Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер Композиции и способы лечения грибковых и бактериальных патогенов
CN108883167A (zh) 2016-03-09 2018-11-23 加州大学洛杉矶分校港口医学中心生物医学研究所 用于预防和治疗外阴阴道念珠菌病的方法和药剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5668263A (en) * 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
US5858378A (en) * 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US7067138B1 (en) * 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US20070077256A1 (en) * 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US8541008B2 (en) * 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
CA2325774C (en) * 1999-12-10 2011-02-08 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Coniothyrium minitans .beta.-(1,3) exoglucanase gene cbeg1
US7241613B1 (en) * 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
UA109105C2 (uk) * 2006-04-17 2015-07-27 Молекула нуклеїнової кислоти, що кодує істотно нетоксичний мутеїн альфа-токсину clostridium perfringens, та істотно нетоксичний мутеїн альфа-токсину clostridium perfringens

Also Published As

Publication number Publication date
WO2006121895A2 (en) 2006-11-16
AU2006244401A1 (en) 2006-11-16
JP2008540453A (ja) 2008-11-20
EP1883421A2 (en) 2008-02-06
US20060083750A1 (en) 2006-04-20
AU2006244401A8 (en) 2006-11-16
EP1883421A4 (en) 2009-12-16
WO2006121895A3 (en) 2007-06-07
AU2006244401B2 (en) 2012-09-06

Similar Documents

Publication Publication Date Title
US10300120B2 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20140127217A1 (en) Pharmaceutical compositions and methods to vaccinate against candidiasis
Sui et al. The vaccines and antibodies associated with Als3p for treatment of Candida albicans infections
EP2448959B1 (en) Hyr1 as a target for active and passive immunization against candida
AU2006244401B2 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US7067138B1 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
AU2012216520A1 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
AU2013203750A1 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
Chandley et al. Role of Vaccines and Monoclonal Antibodies in Systemic Candidiasis: Past and Future Approaches

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20170529